meiyouheng becotatug vedotin for injection nasopharyngeal carcinoma 50mg package

Description

Indication & Scope

MeiYouHeng® Becotatug Vedotin for Injection treats adult patients with recurrent or metastatic nasopharyngeal carcinoma who have received at least one line of prior systemic chemotherapy regimen.

Mechanism: EGFR-targeted antibody-drug conjugate composed of humanized anti-EGFR monoclonal antibody becotatug, cleavable valine-citrulline linker and MMAE microtubule inhibitor payload. It selectively binds EGFR highly overexpressed on nasopharyngeal carcinoma cells, internalizes and releases cytotoxic MMAE payload to disrupt tumor cell microtubule assembly and trigger cancer cell apoptosis.
Drug class: EGFR-directed antibody-drug conjugate; injectable targeted anti-neoplastic agent.
Clinical use: Salvage targeted therapy for recurrent/metastatic nasopharyngeal carcinoma after frontline platinum chemotherapy failure; achieves durable tumor remission for advanced NPC patients with limited treatment options.

Specification

Generic Name	Becotatug Vedotin for Injection
Brand Name	MeiYouHeng
Ingredient	Becotatug Vedotin
Dosage Form	Injection
Package	50mg*1 vial/box
Conditions Treated	Recurrent or metastatic nasopharyngeal carcinoma in adult patients
Taboos	Severe hypersensitivity to anti-EGFR monoclonal antibodies, ADC linker components or auristatin payload derivatives; patients with active severe peripheral neuropathy grade ≥3
Place of origin	China
Prescription type	Prescription-only
Storage Conditions	Unreconstituted lyophilized vials refrigerated at 2°C–8°C, protected from light exposure. Diluted infusion solution must be used within 24 hours refrigerated. Do not freeze powder
Manufacturer	DongYao Pharmaceutical, Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	S20250057
Approval Date	Oct 28, 2025
Shelf Life	24 months

How to use ?

Recommended Dose: 2.5 mg per kilogram of body weight per infusion cycle.

Time: Intravenous slow infusion administered once every 14 days (2-week treatment cycle).

Instructions for use: Reconstitute lyophilized powder with sterile water for injection, dilute in 0.9% sodium chloride solution for 60-minute IV infusion. Conduct routine peripheral nerve function monitoring throughout treatment cycles.

Interaction: Concurrent taxane chemotherapy agents increase peripheral neuropathy severity risk; strong CYP3A4 inhibitors elevate MMAE payload systemic exposure.

Side effects:

1. Common adverse reactions: peripheral sensory neuropathy, fatigue, dry eye, stomatitis, neutropenia, rash.

2. Severe toxicities: grade 3+ peripheral neuropathy, severe neutropenia, interstitial pneumonia.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support